George ScangosThe Cambridge drug company said it took in $2.1 billion in the first three months of 2014, a 51 percent hike from the same period last year and better than the $2 billion consensus of analyst estimates.
As expected, Biogen’s (Nasdaq: BIIB) multiple sclerosis pill, Tecfidera, attained blockbuster status in its first 12 months on the market since its launch in late March 2013. The drug brought in $506 million in the first quarter of 2014, bringing its total revenues since launch to nearly $1.4 billion. While it’s unclear whether Tecfidera is in fact the first drug to exceed $1 billion in sales in its first year, it’s widely expected to soon be beaten by Gilead’s hepatitis C drug, Solvadi, which was launched last December.
Story Source: The above story is based on materials provided by BIOFLASH
Note: Materials may be edited for content and length